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ESM Table 1A  PRISMA-DTA checklist 
Section and Topic Item No. Description Reported on 
Page #(*) or Section 
Title    
Title 1 Identify the report as a systematic review (meta-analysis) of DTA 
studies. 1 
Abstract    
Abstract 2 Abstract checklist for PRISMA-DTA (ESM Table 1B)  Abstract. 
Introduction    
Rationale 3 Describe the rationale for the review in the context of what is 
already known Introduction. 
Clinical role of index test D1 
State the scientific and clinical background, including the 
intended use and clinical role of the index test, and if applicable, 
the rationale for minimally acceptable test accuracy (or minimum 
difference in accuracy for a comparative design). 
Introduction. 
Objectives 4 Provide an explicit statement of question being addressed in terms of participants, index test, and target conditions. Introduction. 
Methods    
Protocol and registration 5 Indicate where the review protocol can be accessed (e.g., web 
address) and provide trial registration number if available. 
Methods and 
Footnote 1. 
Eligibility criteria 6 
Specify study characteristics (participants, setting, index test, 
reference standards, target conditions, and study design) and 
report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility and providing 
rationale. 
Methods ("Data 
sources and search 
strategy" and "Study 
screening and 
selection").** 
Information sources 7 
Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and the date last searched. 
Methods ("Data 
sources and search 
strategy"), ESM 
Table 2. 
Search 8 
Present full search strategies for all electronic databases and other 
sources searched, including any limits used so that they can be 
repeated. 
Methods ("Data 
sources and search 
strategy"), ESM 
Table 2. 
Study selection 9 
State the process for selecting studies (i.e., screening, eligibility, 
whether included in systematic review, and, if applicable, 
included in the meta-analysis). 
Methods ("Study 
screening and 
selection").** 
Data collection process 10 
Describe the methods of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from the investigators. 
Methods ("Study 
screening and 
selection"). 
Definitions for data 
extraction 11 
Provide definitions used in data extraction and classifications of 
target conditions, index tests, reference standards, and other 
characteristics (e.g., study design, clinical setting). 
Methods (Study 
screening and 
selection")**, ESM 
Table 3. 
Risk of bias and 
applicability 12 
Describe methods used for assessing risk of bias in individual 
studies and concerns regarding the applicability to the review 
question. 
Methods ("Appraisal 
of study quality").** 
Diagnostic accuracy 
measures 
13 
State the principal diagnostic accuracy measures reported (e.g., 
sensitivity, specificity) and state the unit of assessment (e.g., per 
patient vs per lesion). 
Methods ("Statistical 
Analysis"), ESM 
Table 5. 
 
(*)
 The page number is referred to the “.doc” file of the final version. ** Partially overlapped with information provided in the Results 
and related ESM. 
 
 
Section and Topic Item No. Description Reported on 
Page # or Section 
Methods    
Synthesis of results 14 
Describe the methods of handling the data, combining the results 
of the studies and describing the variability between studies. This 
could include, but is not limited to (1) handling of multiple 
definitions of the target condition, (2) handling of multiple 
thresholds of test positivity, (3) handling multiple index test 
readers, (4) handling of indeterminate test results, (5) grouping 
and comparing tests, and (6) handling of different reference 
standards. 
Methods ("Statistical 
Analysis").* Further 
elements are reported 
in ESM Table 2-4, 6-
7. 
Meta-analysis D2 Report the statistical methods used for meta-analyses if performed. 
Methods ("Statistical 
Analysis"). 
Additional analyses 16 
Describe the methods of the additional analyses (eg, sensitivity 
or subgroup analyses, meta-regression) if done, indicating which 
were prespecified. 
Methods ("Statistical 
Analysis"), ESM Sec. 
1. 
Results    
Study Selection 17 
Provide the numbers of studies screened, assessed for eligibility, 
included in the review, and included in the meta-analysis if 
applicable, with reasons for exclusions at each stage, ideally with 
a flow diagram. 
Results ("Study 
selection"), Fig. 1,  
ESM Table 4. 
Study characteristics 18 
For each included study, provide citations and present key 
characteristics including (1) participant characteristics 
(presentation, prior testing), (2) clinical setting, (3) study design, 
(4) target condition definition, (5) index test, (6) reference 
standard, (7) sample size, and (8) funding sources.** 
Results ("Study 
characteristics"), 
Table 1, Table 2. 
Risk of bias and 
applicability 19 
Present evaluation of risk of bias and concerns regarding 
applicability for each study. 
Results ("Quality of 
evidence and risk of 
bias", "Publication 
bias and heteroge-
neity of the included 
studies"), Fig. 2, ESM 
Table 7. 
Results of individual 
studies 20 
For each analysis in each study (e.g., unique combination of 
index test, reference standard, and positivity threshold), report 2 
× 2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy 
and confidence intervals, ideally with a forest plot or a receiver 
operating characteristic curve. 
ESM Table 5, Fig. 3, 
ESM Fig. 2. 
Synthesis of results 21 Describe test accuracy, including variability; if meta-analysis 
was done, include results and confidence intervals. 
Results ("Publication 
bias and heteroge-
neity of the included 
studies", "Diagnostic 
meta-analysis for the 
included studies"), 
Fig. 4. 
Additional analyses 23 
Give results of additional analyses if done (e.g., sensitivity or 
subgroup analyses, meta-regression, analysis of index test, failure 
rates, proportion of inconclusive results, and adverse events). 
Results ("Diagnostic 
meta-analysis for the 
included studies", 
"Publication bias and 
heterogeneity in a 
subset of included 
studies", "Diagnostic 
meta-analysis for a 
subset of included 
studies"), ESM Fig. 
1-3, ESM Sec. 1, 
ESM Fig. 4-5.  
 
*
 Partially overlapped with information provided in the Results. ** No funding sources were reported in the included studies. 
Section and Topic Item No. Description Reported on 
Page # or Section 
Discussion    
Summary 24 Summarize the main findings including the strength of the 
evidence. Discussion 
Limitations 25 
Discuss limitations from included studies (e.g., risk of bias and 
concerns regarding applicability) and from the review process 
(e.g., incomplete retrieval of identified research). 
Discussion and  
"Strengths and 
limitations" 
subsection. 
Conclusions 26 
Provide a general interpretation of the results in the context of 
other evidence. Discuss implications for future research and 
clinical practice (e.g., the intended use and clinical role of the 
index test). 
Discussion and 
"Conclusions" 
subsection. 
Other    
Funding 27 For the systematic review, describe the sources of funding and 
other support and the role of the funders. 
Not applicable (no 
public or private 
funding for this 
study). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESM Table 1B  Abstract checklist for PRISMA-DTA 
Section and Topic Item No. Description Reported on the 
Abstract Section 
Title and Purpose    
Title 1 Identify the report as a systematic review (meta-analysis) of DTA studies. Purpose 
Objectives 2 Indicate the research question, including components such as participants, index test, and target conditions. Purpose / Methods 
Methods    
Eligibility criteria 3 Include study characteristics used as criteria for eligibility Methods 
Information sources 4 List the key databases searched and the search dates Methods 
Risk of bias and applicability 5 Indicate the methods of assessing risk of bias and applicability. Methods 
Synthesis of results A1 Indicate the methods for the data synthesis. Methods 
Results    
Included studies 6 
Indicate the number and type of included studies and the 
participants, and relevant characteristics of the studies 
(including the reference standard). 
Results / Methods 
Synthesis of results 7 
Include the results for the analysis of diagnostic accuracy, 
preferably indicating the number of studies and participants. 
Describe test accuracy including variability; if meta-analysis 
was done, include summary results and confidence intervals. 
Results 
Discussion    
Strengths and limitations 9 Provide a brief summary of the strengths and limitations of the 
evidence Conclusions 
Interpretation 10 Provide a general interpretation of the results and the important implications. Conclusions 
Other    
Funding 11 Indicate the primary source of funding for the review. Not applicable 
Registration 12 Provide the registration number and the registry name. Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESM Table 2  Full search strategy 
Database Query Time-point Records 
MEDLINE/PubMed® (("optical" [All Fields] AND "nerve" [All Fields] AND 
"sheath"[All Fields] AND "diameter" [All Fields]) OR 
"ONSD"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) AND 
English[lang]) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
228 
250 
 ("intracranial pressure"[All Fields] OR "intracranial 
hypertension"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) AND 
English[lang]) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
19,474 
19,878 
 ("intracranial pressure"[All Fields] OR "intracranial 
hypertension"[All Fields]) AND ("brain injuries"[All Fields] 
OR "swelling"[All Fields] OR "papilledema"[All Fields]) 
AND ("1980/01/01"[PDAT] : "2018/05/31"[PDAT] {or 
"2017/12/31"[PDAT]}) AND English[lang]) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
4,753 
4,801 
 ("optical" [All Fields] AND "nerve" [All Fields] AND 
"sheath"[All Fields]) AND "diameter" [All Fields]) OR 
"ONSD"[All Fields]) AND ("optic nerve"[All Fields] OR 
"nervus opticus"[All Fields]) AND "ultrasonography"[All 
Fields] AND ("intracranial pressure"[All Fields] OR 
"intracranial hypertension"[All Fields]) AND ("brain 
injuries"[All Fields] OR "swelling"[All Fields] OR 
"papilledema"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) AND 
English[lang]) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
15 
16 
 ("optical" [All Fields] AND "nerve" [All Fields] AND 
"sheath"[All Fields] AND "diameter" [All Fields]) OR 
"ONSD"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
237 
259 
 ("intracranial pressure"[All Fields] OR "intracranial 
hypertension"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
23,230 
23,651 
 ("intracranial pressure"[All Fields] OR "intracranial 
hypertension"[All Fields]) AND ("brain injuries"[All Fields] 
OR "swelling"[All Fields] OR "papilledema"[All Fields]) 
AND ("1980/01/01"[PDAT] : "2018/05/31"[PDAT] {or 
"2017/12/31"[PDAT]}) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
5,514 
5,562 
 (("optical" [All Fields] AND "nerve" [All Fields] AND 
"sheath"[All Fields]) AND "diameter" [All Fields]) OR 
"ONSD"[All Fields]) AND ("optic nerve"[All Fields] OR 
"nervus opticus"[All Fields]) AND "ultrasonography"[All 
Fields] AND ("intracranial pressure"[All Fields] OR 
"intracranial hypertension"[All Fields]) AND ("brain 
injuries"[All Fields] OR "swelling"[All Fields] OR 
"papilledema"[All Fields]) AND ("1980/01/01"[PDAT] : 
"2018/05/31"[PDAT] {or "2017/12/31"[PDAT]}) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
16 
17 
 
 
 
 
 
 
 
 
 
Database Query Time-point Records 
Scopus® ALL (("optical nerve sheath diameter" OR "ONSD") AND 
("optic nerve" OR "nervus opticus") AND 
("ultrasonography")) AND (LIMIT-TO ( LANGUAGE, 
"English")) AND PUBYEAR > 1979 {AND PUBYEAR < 
2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
193 
212 
 
ALL (("intracranial pressure" OR "intracranial hypertension")) 
AND (LIMIT-TO (LANGUAGE, "English")) AND 
PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
57,438 
58,967 
 
ALL (("intracranial pressure" OR "intracranial hypertension") 
AND ("brain injuries" OR "swelling"  OR "papilledema"))) 
AND (LIMIT-TO (LANGUAGE, "English")) AND 
PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
23,336 
24,112 
 
ALL (("optical nerve sheath diameter" OR "ONSD") AND 
("optic nerve" OR "nervus opticus") AND ("ultrasonography") 
AND ("intracranial pressure" OR "intracranial hypertension") 
AND AND (LIMIT-TO (LANGUAGE, "English")) AND 
PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
160 
176 
 
ALL (("optical nerve sheath diameter" OR "ONSD") AND 
("optic nerve" OR "nervus opticus") AND 
("ultrasonography")) AND PUBYEAR > 1979 {AND 
PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
200 
220 
 
ALL (("intracranial pressure" OR "intracranial hypertension")) 
AND PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
65,353 
66,940 
 
ALL (("intracranial pressure" OR "intracranial hypertension") 
AND ("brain injuries" OR "swelling"  OR "papilledema")) 
AND PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
25,851 
26,647 
 
ALL (("optical nerve sheath diameter" OR "ONSD") AND 
("optic nerve" OR "nervus opticus") AND ("ultrasonography") 
AND ("intracranial pressure" OR "intracranial hypertension") 
AND ("brain injuries" OR "swelling" OR "papilledema")) 
AND PUBYEAR > 1979 {AND PUBYEAR < 2018} 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
164 
181 
Science Citation Index® 
Expanded from Web of 
Science® 
(TS=(optical nerve sheath diameter OR ONSD) AND 
TS=(optic nerve OR nervus opticus) AND 
TS=(ultrasonography)) AND LANGUAGE: (English) 
01/01/1985*-31/05/2017 
01/01/1985-31/05/2018 
107 
118 
 
(TS=(“intracranial pressure” OR “intracranial hypertension”)) 
AND LANGUAGE: (English) 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
17,784 
18,196 
 
(TS=("intracranial pressure" OR "intracranial hypertension") 
AND TS=("brain injuries" OR "swelling" OR "papilledema")) 
AND LANGUAGE: (English) 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
1,823 
1,873 
 
(TS=(“optical nerve sheath diameter” OR "ONSD") AND 
TS=(“optic nerve” OR “nervus opticus”) AND 
TS=(“ultrasonography”) AND TS=(“intracranial pressure” OR 
“intracranial hypertension”) AND TS=(“brain injuries” OR 
“swelling” OR “papilledema”)) AND LANGUAGE: (English) 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
3 
5 
 
TS=(optical nerve sheath diameter OR ONSD) AND 
TS=(optic nerve OR nervus opticus) AND 
TS=(ultrasonography) 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
109 
120 
 
TS=(“intracranial pressure” OR “intracranial hypertension”) 01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
19,276 
19,698 
 
TS=("intracranial pressure" OR "intracranial hypertension") 
AND TS=("brain injuries" OR "swelling" OR "papilledema") 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
1,973 
2,024 
 
TS=(“optical nerve sheath diameter” OR "ONSD") AND 
TS=(“optic nerve” OR “nervus opticus”) AND 
TS=(“ultrasonography”) AND TS=(“intracranial pressure” OR 
“intracranial hypertension”) AND TS=(“brain injuries” OR 
“swelling” OR “papilledema”) 
01/01/1985-31/05/2017 
01/01/1985-31/05/2018 
3 
5 
 
* The queries within the Science Citation Index® Expanded from Web of Science database must start from 01/01/1985.  
 
 
Database Query Time-point Records 
ScienceDirect® (*) (“optical nerve sheath diameter” OR "ONSD") AND 
(“optic nerve” OR “nervus opticus”) AND 
(“ultrasonography”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
82 
92 
 
(“intracranial pressure” OR “intracranial hypertension”) 01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
41,498 
43,297 
 
("intracranial pressure" OR "intracranial hypertension") 
AND (“brain injuries” OR “swelling” OR “papilledema”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
17,821 
18,518 
 
(“optical nerve sheath diameter” OR "ONSD") AND 
(“optic nerve” OR “nervus opticus”) AND 
(“ultrasonography”) AND (“intracranial pressure” OR 
“intracranial hypertension”) AND (“brain injuries” OR 
“swelling” OR “papilledema”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
49 
53 
Cochrane Library® via 
Wiley Online Library  (*) 
(“optical nerve sheath diameter” OR "ONSD") AND 
(“optic nerve” OR “nervus opticus”) AND 
(“ultrasonography”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
8 
9 
 
(“intracranial pressure” OR “intracranial hypertension”) 01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
194 
197 
 
("intracranial pressure" OR "intracranial hypertension") 
AND (“brain injuries” OR “swelling” OR “papilledema”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
86 
89 
 
(“optical nerve sheath diameter” OR "ONSD") AND 
(“optic nerve” OR “nervus opticus”) AND 
(“ultrasonography”) AND (“intracranial pressure” OR 
“intracranial hypertension”) AND (“brain injuries” OR 
“swelling” OR “papilledema”) 
01/01/1980-31/12/2017 
01/01/1980-31/05/2018 
2 
2 
 
(*) The English-only search was refined screening manually each record. 
A systematic literature search was performed in the following databases: MEDLINE/PubMed® 
(https://www.ncbi.nlm.nih.gov/pubmed), Scopus® (https://www.scopus.com/search/form.uri?display=basic), Science Citation Index® 
Expanded from Web of Science® (http://apps.webofknowledge.com/), ScienceDirect® (https://www.sciencedirect.com/), and Cochrane 
Library® (http://cochranelibrary-wiley.com/cochranelibrary/search). The search was carried out using the following terms: “optical 
nerve sheath diameter”, “optic nerve”, “nervus opticus”, “ultrasonography”, “brain injuries”, “swelling”, “papilledema”, “intracranial 
pressure”, and “intracranial hypertension”. The search was primarily set by including only original studies published in English in peer-
review sources, followed by a search without language limitations. Additionally, reference lists of the pre-screened studies were 
manually checked, using an iterative approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ESM Table 3  Extracted data in each study assessed for eligibility 
Extracted Data Details 
 
 
Study Reference     Names and surnames of authors, year of  
       publication. 
 
Country      Country/countries in which the study was  
       carried out. 
 
Study design      Type of recruitment. 
 
Gender      Percentage of male patients. 
 
Age       Patient age reported in the study (as mean ± sd
       or median). 
 
Patient number     Number of eligible patients, number of patients 
       with and without intracranial hypertension,  
       number of excluded patients. 
 
Pathology      Diseases reported in the included studies  
       (healthy volunteers and animal models were 
       excluded). 
 
ICP       Intracranial pressure, with intracranial  
       hypertension assumed for ICP >20 mmHg or 
       >25 cm H2O. 
 
Cut-off      Threshold values of optic nerve sheath  
       diameter with reference to gold standard. 
 
Correlation coefficient (r)    Correlation coefficient between mean ONSD 
       and opening ICP measurement. 
 
Sensitivity      Sensitivity calculated from the ROC curve. 
 
Specificity      Specificity calculated from the ROC curve. 
________________________________________________________________________________ 
ICP: intracranial pressure; ONSD: optic nerve sheath diameter. 
 
 
 
 
 
 
 
 
 
 
ESM Table 4  Full text articles excluded, not fitting eligibility criteria 
Excluded Studies Main reason for exclusion 
 
Aduayi et al. 2015     No comparison with gold standard as reference. 
Amini et al. 2013      Cut-off for ICP <25 cmH2O. 
Anas 2014       Study conducted in healthy volunteers. 
Bekerman et al. 2016     No comparison with gold standard as reference. 
Bolesch et al. 2015     No comparison with gold standard as reference. 
Caffery et al. 2014     Cut-off for ICP <25 cmH2O. 
Chelly et al. 2016     No comparison with gold standard as reference. 
Chen et al. 2015       Study conducted in healthy volunteers. 
Chin et al. 2015      No comparison with gold standard as reference. 
Cimilli et al. 2015     No comparison with gold standard as reference. 
Cooley et al. 2015     Study conducted in animal models. 
Dalal 2016       Review article. 
Dip et al. 2016       No comparison with gold standard as reference. 
Di Pasquale et al. 2016      No comparison with gold standard as reference. 
Dubourg et al. 2011     Review article. 
Ebraheim et al. 2018  No comparison with gold standard as reference; some 
patients with only probable intracranial hypertension (not 
defined). 
Geeraerts et al. 2008     Not specified patients in each ICP subgroup. 
Goeres et al. 2016     Study conducted in healthy volunteers. 
Hansen et al. 2016     No comparison with gold standard as reference. 
Heckmann et al. 1998     Review article. 
Hylkema et al. 2016     Review article. 
Kaffery et al. 2014     Cut-off for ICP <25 cmH2O. 
Karami et al. 2015     Study conducted in healthy volunteers. 
Kim et al. 2015      No comparison with gold standard as reference. 
Kim et al. 2014      No comparison with gold standard as reference. 
Komut et al. 2016      No comparison with gold standard as reference. 
Lee et al. 2016       No comparison with gold standard as reference. 
Liu et al. 2017      Cut-off for ICP <25 cmH2O. 
Lochner et al. 2016     No comparison with gold standard as reference. 
Lochner et al. 2015     Review article. 
Lochner et al. 2014     No comparison with gold standard as reference. 
Luberda et al. 2013     Review article. 
Masquère et al. 2013     No comparison with gold standard as reference. 
Mehrpour et al. 2015     No information regarding correlation coefficient. 
Messerer et al. 2013     Review article. 
Min et al. 2015      No comparison with gold standard as reference. 
Moretti and Pizzi 2011     Review article. 
Moretti et al. 2009     Potential patients overlapping with another study. 
Robba et al. 2016      No comparison with gold standard as reference. 
Robba et al. 2015a      No comparison with gold standard as reference. 
Robba et al. 2015b      Review article. 
Sekhon et al. 2014      No comparison with gold standard as reference. 
Shah et al. 2015      No comparison with gold standard as reference. 
________________________________________________________________________________________________ 
 
 
Excluded Studies Main reason for exclusion 
 
Shofty et al. 2012      No comparison with gold standard as reference. 
Singh et al. 2012      Review article.  
Soldatos et al. 2008  No comparison with gold standard as reference; study 
design. 
Soliman et al. 2018 Different and not validated sonographic ONSD quality 
criteria. 
Steinborn et al. 2016      No comparison with gold standard as reference. 
Strumwasser et al. 2011     Not specified patients in each ICP subgroup. 
Tarzamni et al. 2016      No comparison with gold standard as reference. 
Terkawi et al. 2013      Review article. 
Topcuoglu et al. 2015      No comparison with gold standard as reference. 
Ueda et al. 2015       No comparison with gold standard as reference. 
Vaiman et al. 2016      No comparison with gold standard as reference. 
Vaiman et al. 2015      No comparison with gold standard as reference. 
Verdonck et al. 2014      No comparison with gold standard as reference. 
Wang et al. 2015      Cut-off for ICP <25 cmH2O. 
Wang et al. 2018  Study design (ONSD before the lumbar puncture in 60 
patients on admission, with cut-off for ICP <25 cmH2O; 
subsequent grouping of the 25 enrolled patients for ICP 
≤300/>300 mmH2O). 
________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESM Table 5  Diagnostic accuracy parameters estimated for each included study 
________________________________________________________________________________________________ 
Jeon et al. 2017 
TP: 30. FP: 4. FN: 2. TN: 26. Sensitivity: 0.938 (95% CI 0.799‒0.983). Specificity: 0.867 (95% CI 0.703‒0.947). OFC: 
0.903 (95% CI 0.786‒0.955). MCR: 0.097 (95% CI 0.045‒0.214). PPV: 0.882 (95% CI 0.775‒0.930). NPV: 0.929 (95% 
CI 0.799‒0.986). J: 0.804 (95% CI 0.569‒0.908). DOR: 97.5 (95% CI 16.496‒576.293). PLR: 7.031 (95% CI 2.811‒
17.585). NLR: 0.072 (95% CI 0.019‒0.278). 
________________________________________________________________________________________________ 
Robba et al. 2017 
TP: 16. FP: 8. FN: 2. TN: 38. Sensitivity: 0.889 (95% CI 0.672‒0.969). Specificity: 0.826 (95% CI 0.693‒0.909). OFC: 
0.844 (95% CI 0.728‒0.895). MCR: 0.156 (95% CI 0.105‒0.272). PPV: 0.667 (95% CI 0.512‒0.735). NPV: 0.950 (95% 
CI 0.857‒0.991). J: 0.715 (95% CI 0.428‒0.841). DOR: 38 (95% CI 7.255‒199-041). PLR: 5.111 (95% CI 2.666‒9.797). 
NLR: 0.135: (95% CI 0.036‒0.5). 
________________________________________________________________________________________________ 
del Saz-Saucedo et al. 2016 
TP: 18. FP: 1. FN: 1. TN: 10. Sensitivity: 0.947 (95% CI 0.754‒0.991). Specificity: 0.909 (95% CI 0.623‒0.984). OFC: 
0.933 (95% CI 0.747‒0.994). MCR: 0.067 (95% CI 0.006‒0.253). PPV: 0.947 (95% CI 0.8‒0.995). NPV: 0.909 (95% CI 
0.655‒0.992). J: 0.856 (95% CI 0.456‒0.987). DOR: 180 (95% CI 10.129‒3198.825). PLR: 10.421 (95% CI 1.603‒
67.734). NLR: 0.058 (95% CI 0.009‒0.394). 
________________________________________________________________________________________________ 
Rajajee et al. 2011 
TP: 37. FP: 1. FN: 2. TN: 25. Sensitivity: 0.949 (95% CI 0.831‒0.986). Specificity: 0.962 (95% CI 0.811‒0.993). OFC: 
0.954 (95% CI 0.853‒0.983). MCR: 0.046 (95% CI 0.017‒0.147). PPV: 0.974 (95% CI 0.888‒0.999). NPV: 0.926 (95% 
CI 0.805‒0.961). J: 0.910 (95% CI 0.7‒0.971). DOR: 462.5 (95% CI 39.771‒5378.41). PLR: 24.667 (95% CI 3.604‒
168.804). NLR: 0.053 (95% CI 0.014‒0.206).  
________________________________________________________________________________________________ 
Moretti and Pizzi 2009 
TP: 18. FP: 9. FN: 1. TN: 25. Sensitivity: 0.947: (95% CI 0.754‒0.991). Specificity: 0.735 (95% CI 0.569‒0.854). OFC: 
0.811 (95% CI 0.678‒0.847). MCR: 0.189 (95% CI 0.153‒0.322). PPV: 0.667 (95% CI 0.536‒0.702). NPV: 0.962 (95% 
CI 0.825‒0.998). J: 0.683 (95% CI 0.392‒0.760). DOR: 50 (95% CI 5.807‒430.528). PLR: 3.579 (95% CI 2.024‒6.330). 
NLR: 0.072 (95% CI 0.011‒0.487). 
________________________________________________________________________________________________ 
Kimberly et al. 2008 
TP: 7. FP: 1. FN: 1. TN: 6. Sensitivity: 0.875 (95% CI 0.529‒0.978). Specificity: 0.857 (95% CI 0.487‒0.974). OFC: 
0.867 (95% CI 0.549‒0.988). MCR: 0.133 (95% CI 0.012‒0.451). PPV: 0.875 (95% CI 0.577‒0.989). NPV: 0.857 (95% 
CI 0.517‒0.987). J: 0.732 (95% CI 0.094‒0.976). DOR: 42 (95% CI 2.136‒825.715). PLR: 6.125 (95% CI 0.979‒38.312). 
NLR: 0.146 (95% CI 0.023‒0.35). 
________________________________________________________________________________________________ 
Geeraerts et al. 2007 
TP: 15. FP: 3. FN: 1. TN: 12. Sensitivity: 0.938 (95% CI 0.717‒0.989). Specificity: 0.8 (95% CI 0.548‒0.930). OFC: 
0.871 (95% CI 0.677‒0.932). MCR: 0.129 (95% CI 0.068‒0.323). PPV: 0.938 (95% CI 0.761‒0.994). NPV: 0.923 (95% 
CI 0.706‒0.993). J: 0.738 (95% CI 0.349‒0.86). DOR: 60 (95% CI 5.514‒652.902). PLR: 4.688 (95% CI 1.69‒12.999). 
NLR: 0.078 (95% CI 0.012‒0.53). 
________________________________________________________________________________________________ 
 
TP: True Positives (Sensitivity * Prevalence). FP: False Positives [(1－Specificity) * (1－Prevalence)]. FN: False Negatives 
[(1－Sensitivity) * Prevalence]. TN: True Negatives [(Specificity * (1－Prevalence)]. CI: Confidence interval. OFC: Overall Fraction 
Correct, also referred as Accuracy [(TP + TN) / (TP + FP + FN + TN)]. MCR: Mis-Classification Rate (1－OFC). PPV: Positive 
Predictive Value [TP / (TP + FP]. NPV: Negative Predictive Value [TN / (FN + TN)]. J: Youden’s J (Sensitivity ＋ Specificity－1). 
DOR: Diagnostic Odds Ratio [Sensitivity/(1－Sensitivity)] / [(1－Specificity) / Specificity]. PLR: Positive Likelihood Ratio 
[Sensitivity / (1－Specificity)]. NLR: Negative Likelihood Ratio [(1－Sensitivity) / Specificity].  
All calculations were performed by using the R statistical environment (version 3.4.2. R Foundation for Statistical Computing), with 
“mada” package (version 0.5.8. Doebler P. “mada: Meta-Analysis of Diagnostic Accuracy”) and “madad” function. For more details, 
see: https://cran.r-project.org/web/packages/mada/mada.pdf. 
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ESM Table 6  Overall quality assessment of the diagnostic accuracy studies enrolled in the meta-analysis, following the GRADE system 
 
Quality assessment Summary of findings 
No. of patients Effect 
Quality 
 
No. of 
studies 
 
Design 
 
Limitations 
 
Indirectness 
of patients, 
intervention 
and 
comparator 
 
Inconsistency 
 
Imprecision 
 
Other 
considerations Intracranial 
hypertension1 
Absence of 
intracranial 
hypertension2 
Relative 
(95% CI) 
Absolute 
(95% CI)3 
 
7 studies 
(320 adult 
patients) 
 
6 prospec-
tive obser-
vational 
studies, 1 
diagnostic 
phase I-II 
study  
 
Some 
limitations 
exist4 
 
Serious5 
 
Serious6 
 
Serious7 
 
The QUADAS-
2 outcome sug-
gested a high 
risk of bias for 
3 studies8 
 
151 
 
169 - 
 
From 
34.058 to 
177.034 
⊕○○○ 
VERY LOW 
 
1
 Patients with intracranial hypertension [True Positives (patients with intracranial hypertension) and False Negatives (patients incorrectly classified has not having intracranial hypertension)].  
2
 Patients with absence of intracranial hypertension [True Negatives (patients without intracranial hypertension) and False Positives (patients incorrectly classified has having intracranial 
hypertension).  3 95% Confidence interval (CI) of the conventional pooled diagnostc odds ratio (DOR) calculated with the “madad” function of the R “mada” package (version 0.5.8. Doebler 
P. “mada: Meta-Analysis of Diagnostic Accuracy”).  4 Enrollment of patient based on investigator availability (2 studies).  5 Prevalence of males (3 studies), prevalence of females (2 studies), 
adult patients (7 studies), absence of traumatic brain injury (TBI) (1 study); absence of invasive ICP monitoring in patients with severe TBI (1 study), different cut-off values for intracranial 
hypertension definition (>20 mmHg in 5 studies, >25 cmH2O in 2 studies).  6 Wide variation in the DOR estimates, wide 95% CIs.  7  Small (4 studies) or very small (3 studies) samples size; 
failure to adequately control confounding [not simultaneous measurement of intracranial pressure (ICP) between invasive methods and optic nerve sheath diameter (ONSD)] (3 studies); 
measurements obtained in patients with relatively well-controlled ICP (1 study); differences in scans; majority of scans for ONSD measurements were performed by a single experienced 
operator, while some were performed by a second investigator with a limited experience (1 study).  8 For more details, see ESM Table 7. 
 
Each domain was evaluated according to Ryan R, Hill S (2016) How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. Version 3.0 December 2016. 
Available on: http://cccrg.cochrane.org/author-resources (last access: June 15, 2018). The table structure and quality of evidence were showed according to Schünemann H, Brożek J, Guyatt 
G, Oxman A (2013) GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. Available on: 
https://gdt.gradepro.org/app/handbook/handbook.html (last access: May 19, 2018), and Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, 
Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schünemann HJ (2013) GRADE guidelines: 12. Preparing Summary of Findings tables - binary outcomes. J 
Clin Epidemiol 66:158-172 (doi: 10.1016/j.jclinepi.2012.01.012). 
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ESM Table 7  Application of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 for each included study 
________________________________________________________________________________________________________________________________________________________ 
Study       Risk of Bias       Applicability Concerns 
                                                       ___________________________________________________________               ___________________________________________ 
 
    Patient  Index  Reference  Flow and  Patient  Index  Reference 
    Selection Test  Standard  Timing   Selection Text  Standard 
________________________________________________________________________________________________________________________________________________________ 
 
Jeon et al. 2017       ○     ?       ○       ●       ○     ?       ○ 
Robba et al. 2017      ○     ○       ○       ○       ○     ○       ○ 
del Saz-Saucedo et al. 2016     ○     ○       ○       ●       ○     ○       ○ 
Rajajee et al. 2011      ○     ○       ○       ○       ○     ○       ○ 
Moretti and Pizzi 2009      ○     ○       ○       ○       ○     ○       ○ 
Kimberly et al. 2008      ?     ○       ○       ○       ?     ○       ○ 
Geeraerts et al. 2007      ●     ○       ○       ●       ?     ○       ○ 
________________________________________________________________________________________________________________________________________________________ 
 
○ = low risk; ● = high risk; ? = unclear risk. 
Domain 1: Patient Selection  
Risk of Bias (RB): Could the selection of patients have introduced bias? [Signaling question (SQ)1: Was a consecutive or random sample of patients enrolled? SQ2: Was a 
case-control design avoided? SQ3: Did the study avoid inappropriate exclusions?].  
 
Domain 2: Index Test 
RB: Could the conduct or interpretation of the index test have introduced bias? (SQ1: Were the index test results interpreted without knowledge of the results of the reference 
standard? SQ2: If a threshold was used, was it prespecified?). 
 
Domain 3: Reference Standard 
RB: Could the reference standard, its conduct, or its interpretation have introduced bias? (SQ1: Is the reference standard likely to correctly classify the target condition? 
SQ2: Were the reference standard results interpreted without knowledge of the results of the index test?). 
 
Domain 4: Flow and Timing 
RB: Could the patient flow have introduced bias? (SQ1: Was there an appropriate interval between the index test and reference standard? SQ2: Did all patients receive the 
same reference standard? SQ3: Were all patients included in the analysis?). 
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ESM Fig. 1 Evaluation of publication bias in a subset of included study (intracranial hypertension 
assumed for ICP >20 mmHg): Funnel plot for the trim and fill method. 
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ESM Fig. 2 Sensitivity (A) and specificity (B) of sonographic ONSD compared with invasive ICP measurement in a subset of included study (intracranial 
hypertension assumed for ICP >20 mmHg). 
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ESM Fig. 3  HSROC curve of sonographic ONSD compared with invasive ICP measurement for 
diagnosis of intracranial hypertension, in a subset of included studies (intracranial hypertension 
assumed for ICP >20 mmHg). The HSROC curve was not extrapolated beyond the range of the 
original data. 
 
 
 
18 
 
ESM Sec. 1  Further analyses by assuming correlation coefficient as effect size 
We performed additional analyses in the same studies selected for diagnostic meta-analysis, assuming 
the correlation coefficient (r) between the means of sonographic ONSD and invasive ICP 
measurements as effect size. The pooled r was 0.701 (95% CI 0.650‒0.760), whereas the pooled r-
to-z transformed correlation coefficients was 0.842 (95% CI 0.722‒0.960). The DerSimonian-Laird 
random-effects (RE) model was applied to the Fisher’s r-to-z transformed correlation coefficients. 
The forest plots of the Fisher’s r-to-z transformed correlation coefficients and the z-values back-
transformed to r-space are presented in ESM Fig. 4. The RE model was statistical significant (p 
<0.001), without heterogeneity (Q = 6.876, p = 0.332; I2 = 12.74%). An extensive panel of funnel 
plots found as all included studies fell within the pseudo-confidence region (ESM Fig. 5). By entering 
ONSD threshold values as moderator in the RE model, no statistical significance for this covariate 
was found (p = 0.248), without addition of heterogeneity (Q = 5.428, p = 0.366; I2 = 7.89%). Finally, 
the same RE model was evaluated in the subset of five studies that assumed intracranial hypertension 
for ICP >20 mmHg, reaching statistical significance (p <0.001) without heterogeneity (Q = 3.844, p 
= 0.427; I2 = 0.00%). 
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ESM Fig. 4  Forest plots of the Fisher’s r-to-z transformed correlation coefficients (A) and the z-
values back-transformed to r-space (B). 
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ESM Fig. 5  Funnel plots of the DerSimonian-Laird random-effects model applied to the Fisher’s r-
to-z transformed correlation coefficients. 
 
 
